Condition
Non-Hodgkin Lymphoma Refractory/ Relapsed clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Non-Hodgkin Lymphoma Refractory/ Relapsed clinical trials that are recruiting, at sites in 4 countries (most in United States (3), Australia (1), Canada (1)). By phase: Phase 2 (2), Phase 3 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 4Countries
Newest Non-Hodgkin Lymphoma Refractory/ Relapsed clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Ruxolitinib plus pembrolizumab for relapsed or refractory Hodgkin and non-Hodgkin lymphomas | Phase 2 | New York, New York | Recruiting | Dec 16, 2025 |
| MB-CART19.1 CAR-T for adults with relapsed or refractory CD19-positive non-Hodgkin lymphoma. | Phase 2 | Amman | Recruiting | Dec 9, 2025 |
| Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma | Phase 3 | Gilbert, Arizona and 43 other locations | Recruiting | Sep 23, 2025 |
| Safety testing of LTZ-301 in adults with relapsed or refractory B‑cell non-Hodgkin lymphoma | Phase 1 | Duarte, California and 5 other locations | Recruiting | Aug 14, 2025 |
All recruiting trials (4)
-
Ruxolitinib plus pembrolizumab for relapsed or refractory Hodgkin and non-Hodgkin lymphomas
This trial will try adding ruxolitinib to pembrolizumab to see if it is safe and helps people whose Hodgkin or non-Hodgkin lymphomas have come back or did not respond to prior treatment.
-
MB-CART19.1 CAR-T for adults with relapsed or refractory CD19-positive non-Hodgkin lymphoma.
This study will try a single infusion of MB-CART19.1 CAR-T cells in adults with relapsed or refractory CD19-positive non-Hodgkin lymphoma to see if it can reduce disease and is safe.
-
Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma
This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.
-
Safety testing of LTZ-301 in adults with relapsed or refractory B‑cell non-Hodgkin lymphoma
This trial will test whether LTZ-301 is safe and how it behaves in adults whose B‑cell non-Hodgkin lymphoma has come back or not responded after at least two prior treatments.
Related topics
Quick answers
How many Non-Hodgkin Lymphoma Refractory/ Relapsed clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in United States (3 trials), Australia (1 trial), Canada (1 trial), Jordan (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 3: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.